Associations - ESR1 mutation

ESR1 mutation	Estrogen Receptor Positive Breast Cancer	ESR1 mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ESR1 mutation	HER2 Negative Breast Cancer	ESR1 mutation	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ESR1 mutation	HER2 Negative Breast Cancer	ESR1 mutation	HER2 Negative Breast Cancer	lasofoxifene Sensitive: C2 – Inclusion Criteria lasofoxifene Sensitive : C2	lasofoxifene Sensitive: C2 – Inclusion Criteria lasofoxifene Sensitive : C2
ESR1 mutation	Breast Cancer	ESR1 mutation	Breast Cancer	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2
ESR1 mutation	Breast Cancer	ESR1 mutation	Breast Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
ESR1 mutation	HER2 Negative Breast Cancer	ESR1 mutation	HER2 Negative Breast Cancer	abemaciclib + AZD9833 Sensitive: C3 – Early Trials abemaciclib + AZD9833 Sensitive : C3	abemaciclib + AZD9833 Sensitive: C3 – Early Trials abemaciclib + AZD9833 Sensitive : C3
ESR1 mutation	Breast Cancer	ESR1 mutation	Breast Cancer	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
ESR1 mutation	Breast Cancer	ESR1 mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
ESR1 mutation	HER2 Negative Breast Cancer	ESR1 mutation	HER2 Negative Breast Cancer	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3